Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nastech and Amylin sign diabetes nasal spray deal
Preclinical studies of the formulation have been completed in preparation for initiating studies to determine feasibility in human subjects. Under the terms of the agreement, Nastech will receive
Preclinical studies of the formulation have been completed in preparation for initiating studies to determine feasibility in human subjects. Under the terms of the agreement, Nastech will receive
The agreement, signed in July 2004, provided Schering AG with exclusive commercialization rights to Alprox-TD in Europe, Russia, the Middle East, South Africa, Australia and New Zealand. NexMed
According to the company, preliminary analyses of information from the 13-week toxicology studies in animals have revealed various new observations which appear consistent with intense immune stimulation in
In the alliance, Medarex intends to use its UltiMab technology to create antibodies to targets provided by Euroscreen. Under the terms of the agreement, Euroscreen has granted Medarex
Citing unnamed sources close to the deal, the newspaper revealed that the deal could be announced today after a J&J official said the company planned to hold an
In May 2004, the two companies forged a strategic antibody alliance to jointly develop new antibody-based therapeutics against a range of illnesses. As part of the collaboration, Novartis
BioSeek will apply its proprietary BioMap systems in an effort to characterize the mechanisms of action of the leukocyte selective anti-inflammatory drugs (LSAIDs), which make up Inflazyme's respiratory
Prezista, co-administered with 100mg ritonavir (Prezista/rtv) and with other antiretroviral agents, is indicated for the treatment of HIV infection in antiretroviral treatment-experienced adult patients, such as those with
The trial, conducted by DeCode under a research collaboration and licensing agreement with Cephalon, was based upon DeCode's discovery of variants in the gene encoding the MAP3K9 kinase
TACI-Ig is a soluble fusion protein that neutralizes molecules implicated in the pathogenesis of several autoimmune diseases. TACI-Ig appeared to be well tolerated across the full range of